News
NTHI
3.150
-9.48%
-0.330
NeOnc Technologies Holdings Says FDA Reschedules End-Of-Phase 1 Meeting For Oral NEO212 To November 23
Benzinga · 1d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 1d ago
NeOnc Reports Improved Interim NEO100 Phase 2a Response Rate
TipRanks · 2d ago
Roth MKM Reaffirms Their Buy Rating on NeOnc Technologies Holdings, Inc. (NTHI)
TipRanks · 2d ago
NeOnc Technologies reports updated interim results from NEO100-01 study
TipRanks · 3d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 3d ago
Weekly Report: what happened at NTHI last week (1109-1113)?
Weekly Report · 4d ago
NeOnc Technologies Reports FDA End-of-Phase Meeting for NEO100
TipRanks · 11/13 22:32
Biotech Stocks Rally: ADXN Soars 71%, ENGN Jumps 26%, NTHI Gains 12%, PRQR Rises 10%
NASDAQ · 11/12 18:45
BTIG Maintains $15 Price Target on NEO100 as Encouraging Phase 2a Results Support Regulatory Potential
TipRanks · 11/12 11:56
NeOnc Gets FDA Meeting On NEO100 Accelerated Approval Path
NASDAQ · 11/11 14:08
NeOnc granted Type B End-of-Phase meeting by FDA for intranasal NEO100
TipRanks · 11/11 13:05
Biotech Stocks In Focus: PEPG Jumps 114%, ZURA Rises 15%, NTHI Gains 13%
NASDAQ · 11/10 18:33
NeOnc Technologies CEO Amir Heshmatpour Buys 70K Shares At Average Price Of $3.29/Share
Benzinga · 11/09 13:39
Weekly Report: what happened at NTHI last week (1102-1106)?
Weekly Report · 11/09 09:18
NeOnc Maintained at Buy with $20 Price Target on Promising NEO100 Results and Pipeline Potential
TipRanks · 11/07 00:05
Roth MKM Reaffirms Their Buy Rating on NeOnc Technologies Holdings, Inc. (NTHI)
TipRanks · 11/06 19:45
NeOnc Reports Third-Quarter Results and Clinical Progress
TipRanks · 11/05 23:26
NeOnc Technologies Holdings GAAP EPS of -$0.28 misses by $0.09
Seeking Alpha · 11/05 20:25
NeOnc Technologies Q3 EPS $(0.28) Misses $(0.24) Estimate
Benzinga · 11/05 14:19
More
Webull provides a variety of real-time NTHI stock news. You can receive the latest news about NeOnc Technologies Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTHI
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).